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Smoking Cessation Interventions in Clinical Practice
J. Cornuz*
Department of Ambulatory Care and Community Medicine, Lausanne University Hospital,
CH-1011 Lausanne, Switzerland
Objectives. Physicians are in a unique position to advise smokers to quit by integrating the various aspects of nicotine
dependence. This review provides an overview of interventions for smokers presenting in a clinical setting.
Results. Strategies used for smoking cessation counselling differ according to patient’s readiness to quit. For smokers who
do not intend to quit smoking, physicians should inform and sensitise them about tobacco use and cessation. For smokers
who are dissonant, physicians should use motivational strategies, such as discussing barriers to cessation and their solu-
tions. For smokers ready to quit, the physician should show strong support, help set a quit date, prescribe pharmaceutical
therapies for nicotine dependence, such as nicotine replacement therapy (i.e., gum, transdermal patch, nasal spray, mouth
inhaler, lozenges, micro and sublingual tablets) and/or bupropion (atypical antidepressant thought to work by blocking
neural reuptake of dopamine and/or nor epinephrine), with instructions for use, and suggest behavioural strategies to pre-
vent relapse. The efficacy of all of these pharmacotherapies is comparable, roughly doubling cessation rates over control
conditions. Varenicline is a promising new effective drug recently approved by many health authorities.
Conclusion. Physician counselling and pharmacotherapeutic interventions for smoking cessation are among the most cost-
effective clinical interventions.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Smoking is associated with a range of diseases, caus-
ing a high level of morbidity and mortalityand is one
of the leading causes of preventable death, with more
than 4.9 million smokers worldwide dying each year
from smoking-related illnesses. Stopping smoking
has major health benefits.1 Smokers who quit before
the age of 35 can anticipate a life expectancy similar
to those who have never smoked.2 Quitting at any
age provides both short and long-term benefits.
Middle-aged quitters gain improvements in health
and reduce their excess risk of death. Despite the
well-known health consequences of tobacco and the
benefits of quitting, a quarter to a third of the adult
population in industrialized countries continues to
smoke. Although the majority of current smokers
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E-mail address: jacques.cornuz@chuv.ch1078–5884/000397+ 08 $32.00/0  2007 European Society for Vasculwish to quit smoking, and effective interventions exist
for tobacco users,3,4 very few request or receive formal
smoking cessation interventions, even where there are
comprehensive national smoking cessation services
such in the United Kingdom. Physicians are in
a unique position to intervene; yet studies suggest
that smokers are not consistently identified or treated
in clinical settings.5 This overview of interventions for
smokers draws heavily on recent clinical practice
guidelines for treating tobacco use and dependence,
which were based upon qualitative and quantitative
reviews of published clinical research.3,4,6,7
General Recommendations
Even brief advice to quit offered by a physician can
produce abstinence rates of 5e10%, which would
have a significant public health impact if it were pro-
vided routinely.8,9 Unfortunately, surveys of smokers
indicate that they receive such advice from their
physicians less than half the time.5e8 One-reasonar Surgery. Published by Elsevier Ltd. All rights reserved.
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they have become demoralized because so few of
their patients follow this advice. This is an under-
standable reaction when a behaviour goes unre-
warded. However, physicians should realize that
even when their advice does not produce an immedi-
ate quit attempt by a patient, it may very well move
the patient further towards the difficult decision to
quit smoking. Smoking cessation should be consid-
ered as a process of change through successive stages
requiring counselling tailored to smokers’ motivation
to quit. Application of this model improves physi-
cians’ performance on one-year smoking cessation.10
Each smoker should be encouraged to completely
abstain from smoking and should be warned that
other tobacco products, such as smokeless tobacco,
are associated with significant health risks. Smoking
reduction has been proposed as an alternative ap-
proach for smokers.11 Even though this approach is
promising, especially for heavy smokers who suffer
from tobacco-related diseases, such as chronic ob-
structive pulmonary disease, its effectiveness remains
a research question under scrutiny. The recommended
clinical attitude should be to advise patients to quit
rather than reduce smoking. Indeed, it is unlikely
that a once-heavy smoker would be able to maintain
light or infrequent smoking without resorting to his
or her old smoking patterns. Indeed, even lighter
smoking (less than 5 cigarettes per day) has been asso-
ciated with elevated health risks,12 particularly car-
diovascular diseases. Strategies aimed at gradual
reduction of smoking without any medication, versus
quitting ‘‘cold turkey,’’ appear to lead to continued
craving and prolonged withdrawal symptoms in to-
bacco users. Smokers compensate by taking more
and/or deeper puffs per cigarette when they attempt
to reduce their smoking. However, cutting down with
nicotine replacement therapy (NRT) can lead to sus-
tained ‘‘real’’ reductions in smoke intake when as-
sessed by carbon monoxide levels.13 As a result,
several European countries the licence for the use of
NRT has been extended to use it for reducing tobacco
usage as well as for abrupt cessation of tobacco usage.
Clinical practice guidelines recommend that doc-
tors follow the ‘‘5 A’s’’ (Table 1) in initiating assess-
ment and intervention with tobacco users. The ‘‘5
A’s’’ comprise:
1) asking the patient if s/he uses tobacco; identify
and document tobacco use status for every patient
at every visit; 2) advising the patient to quit tobacco
use; 3) assessing the patient’s willingness to quit
tobacco use; 4) assisting the patient in his/her quit
attempt; and 5) arranging follow-up contacts and
relapse prevention.
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ing status during visits.4 According to the guidelines,
the physician then advises the patient to quit smoking
in a clear (‘‘It is important for you to quit smoking now,
and I can help you. Cutting down while you are ill is
not enough.’’) and strong manner (‘‘As your doctor, I
need you to know that quitting smoking is the most
important thing you can do to protect your health
now and in the future. The clinic staff and I will help
you.’’). The advice should also be personalized for
the patient, highlighting his/her particular situation.
For example, the advice may be tied to the patient’s
health (‘‘Your smoking is only prolonging your cough
and putting you at risk for long-term respiratory prob-
lems such as chronic bronchitis or emphysema.’’) and
the impact smoking might have on children (‘‘You are
putting your children at risk of asthma, ear infections
and other diseases by exposing them to second-hand
smoke.’’).
Intervention for Smokers Unwilling to Quit
Intervention efforts will not be successful without
sufficient motivation or ‘‘readiness’’ to quit smoking
on the part of the smoker. For the patient who is pres-
ently unwilling to quit smoking, recommending
entering a smoking cessation program may be pre-
mature and ineffective. The US practice guidelines
suggest following the ‘‘5 R’s’’ motivational interven-
tion as listed Table 2:4 Relevance, Risks, Rewards,
Roadblocks, and Repetition. Such a patient should
be asked to: 1) identify why quitting smoking is per-
sonally relevant to the patient (e.g., patient’s own
health such as bypass occlusion or reducing growth
rate of small aneurysms; health of patient’s children;
prior ability to quit, for example for women while
pregnant); 2) identify potentially negative conse-
quences, or risks, of tobacco use (e.g., exacerbation
of cough; long-term risk of cardiovascular problems
and cancer; risks to children of breathing her
Table 1. The ‘‘5 A’s’’ for smoking cessation intervention
Ask about tobacco use. Identify and document tobacco use
status for every patient at every visit.
Advise to quit. In a clear, strong and personalized
manner urge every tobacco user to quit.
Assess willingness to
make a quit attempt.
Is the tobacco user willing to make
a quit attempt at this time?
Assist in quit attempt. For the patient willing to make a quit
attempt, use counseling and
pharmacotherapy to help him
or her quit.
Arrange follow-up. Schedule follow-up contact, preferably
within the first week after the quit date.
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Relevance Encourage the patient to indicate why quitting is personally relevant, being as specific as possible. Motivational
information has the greatest impact if it is relevant to a patient’s disease status or risk, family or social situation (e.g.,
having children in the home), health concerns, age, gender, and other important patient characteristics (e.g., prior
quitting experience, personal barriers to cessation).
Risks The clinician should ask the patient to identify potential negative consequences of tobacco use. The clinician may
suggest and highlight those that seem most relevant to the patient. The clinician should emphasize that smoking low-
tar/low-nicotine cigarettes or use of other forms of tobacco (e.g., smokeless tobacco, cigars, and pipes) will not
eliminate these risks. Examples of risks are:
 Acute risks: Shortness of breath, exacerbation of asthma, harm to pregnancy, impotence, infertility, increased se-
rum carbon monoxide.
 Long-term risks: Heart attacks and strokes, exacerbation of peripheral arterial disease, lung and other cancers (lar-
ynx, oral cavity, pharynx, esophagus, pancreas, bladder, cervix), chronic obstructive pulmonary diseases (chronic
bronchitis and emphysema), long-term disability and need for extended care.
 Environmental risks: Increased risk of lung cancer and heart disease in spouses; higher rates of smoking by chil-
dren of smokers; increased risk for low birth weight, SIDS, and respiratory infections in children of smokers.
Rewards The clinician should ask the patient to identify potential benefits of stopping tobacco use. The clinician may suggest
and highlight those that seem most relevant to the patient. Examples of rewards follow:
Improved health; Food will taste better; Improved sense of smell; Save money; Feel better about yourself; Home, car,
clothing, breath will smell better; Can stop worrying about quitting; Set a good example for children.
Roadblocks The clinician should ask the patient to identify barriers or impediments to quitting and note elements of treatment
(problem solving, pharmacotherapy) that could address barriers. Typical barriers might include:
Withdrawal symptoms; Fear of failure; Weight gain; Lack of support; Depression; Enjoyment
Repetition The motivational intervention should be repeated every time an unmotivated patient visits the clinic setting. Tobacco
users who have failed in previous attempts should be told that most people make repeated quit attempts before they
are successful.‘‘second-hand smoke;» increased probability that chil-
dren will become smokers themselves); 3) identify re-
wards associated with cessation (e.g., improved sense
of taste and smell; clothes, house, car will smell better;
financial savings); 4) identify roadblocks or barriers to
quitting and note treatment elements that could ad-
dress them (e.g., withdrawal symptoms, such as irrita-
bility; appetite increase, risk of depression, could be
attenuated by pharmacotherapy; lack of social sup-
port for quitting could be remedied by joining a cessa-
tion clinic or support group). Finally, 5) the doctor
should repeat this information each time the patient
is seen in the clinic.
Preparation for the Quitting Process
As the doctor has the opportunity to assist the pa-
tient’s quit attempt, the intervention should comprise
the following: 1) helping the patient with a quit plan;
2) providing practical counselling (problem solving/
skills training); 3) providing intra-treatment social
support; 4) helping the patient obtain extra-treatment
support; 5) recommending the use of approved phar-
macotherapy, except in special circumstances; 6) pro-
viding supplementary materials. In detail, these
recommendations imply that the physician should in-
struct the patient to do the following to prepare to quit
(‘‘STAR’’ acronym):4 1) Set a quit date for as soon as
possible; 2) Tell family, friends, and co-workers about
quitting and request understanding and support; 3)
Anticipate challenges to the planned quit attempt (in-
cluding nicotine withdrawal symptoms), particularlyduring the critical first few weeks; 4) Remove tobacco
products from his/her environment and, prior to quit-
ting, avoid smoking in places where spending a lot of
time (e.g., work, home, car).
The physician should then provide the patient with
some basic didactic information about quitting
smoking.
1) Smoking represents an addiction to nicotine. There-
fore smoking cessation must be undertaken as seri-
ously as one would approach any other drug
addiction. Willpower alone is often insufficient.
The patient must make quitting smoking his/her
top priority.
2) The goal should be total tobacco abstinence after
the quit date.
3) The patient can expect to experience unpleasant nic-
otine withdrawal symptoms (e.g., mood disturbance,
insomnia, irritability, difficulty concentrating, in-
creased appetite and weight gain). For most individ-
uals, these symptoms peak within a few days of
quitting and most of them dissipate gradually to
return to baseline levels after about 3e4 weeks.
4) The physician can help the patient identify ‘‘high-
risk’’ or dangerous situations. These are events, in-
ternal states, or activities that increase the risk of
smoking or relapse due to their past association
with smoking (e.g., negative emotional states, being
around other smokers, drinking alcohol). These sit-
uations should be avoided early on, if at all possible.
5) The doctor can help the patient select cognitive and
behavioural coping skills for use when s/he
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amples of cognitive coping skills are: reminding
him/herself reasons for quitting; telling him/herself
that urgewill pass; and repeating the phrase, ‘‘Smok-
ing is not an option.’’ Behavioural coping skills in-
clude: leaving the situation, engaging in some
distracting activity, taking deep breaths, and seeking
social support.
The doctor should also provide support within the
clinic by: 1) encouraging the patient in the quit at-
tempt (e.g., note that effective tobacco dependence
treatments are now available; remind them that one-
half of all people who have ever smoked have now
quit; communicate belief in the patient’s ability to
quit); 2) communicating caring and concern (e.g. ask-
ing how the patient feels about quitting; directly ex-
press concern and willingness to help; be open to
the patient’s expression of fears of quitting, difficulties
experienced, and ambivalent feelings); 3) encouraging
the patient to talk about the quitting process by asking
about reasons why the patient wants to quit, concerns
or worries about quitting, success the patient has
achieved, and difficulties encountered while quitting.
Eventually, the patient should be assisted with obtain-
ing social support outside of the clinic environment.
The clinician should train the patient in support solic-
itation skills (e.g., practice requesting social support
from family, friends, and co-workers; aid a patient
in establishing a smoke-free home) and prompt sup-
port seeking in the patient (e.g., help the patient iden-
tify supportive others, inform patients of community
resources such as hotlines). A busy clinician may be
tempted to hand one or more of the available self-
help booklets to a patient who smokes, instead of pro-
viding the personal advice called for by the ‘‘5 A’s.’’
The clinical practice guidelines found that there was
insufficient evidence to support the use of self-help
materials.4
Treatment of Nicotine Dependence
Over the past decade there has been a notable increase
in the number of available pharmacotherapies for treat-
ing tobacco dependence. The current recommended
first line therapies are nicotine replacement therapy
(NRT) and Bupropion.4,5
Nicotine replacement therapy (NRT)
Nicotine replacement therapies help smokers, who
are nicotine dependent, and include transdermal
patches, gum, nasal spray, mouth inhaler, sublingual
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ment for smokers attempting to quit, with more than
90 randomised trials comparing different forms of
NRT with non-NRT controls. Trials have generally re-
cruited smokers of >10 cigarettes per day. Not all
NRT types are available in all countries. Few trials
of the sublingual tablets and lozenges have been pub-
lished, but the consistency of the findings for other
types supports an assumption that these formulations
are also effective. All NRT have been shown to be ef-
fective, roughly doubling cessation rates over control
conditions.4 They work by replacing the nicotine in
the cigarettes and reducing this gradually. NRT also
provides a background level of nicotine that reduces
craving and withdrawal. The hypothesis is that by re-
placing the nicotine that smokers receive from ciga-
rettes, the craving to smoke and the symptoms of
abstinence will be alleviated. Nicotine is released
from the different pharmaceutical formulations to
maintain a plasma nicotine level concentration that
is sufficient to decrease the desire to smoke.
A systematic review of fourteen randomised con-
trolled trials evaluating the efficacy of gum performed
in cessation clinics showed that success rates were sig-
nificantly higher (27% and 23%) than with placebo
gum (18% and 13%) at 6 and 12 months, respectively.14
These data also suggest that proper use of nicotine
gum in general medical practices will increase the
rate of cessation.15 Transdermal systems may be
more effective in a primary practice setting than nico-
tine gum.4 Furthermore, such a therapy tends to dou-
ble the quitting rates associated with whatever
behavioural intervention is used. In one study, for ex-
ample, 305 patients participating in a behavioural
smoking cessation program were randomly assigned
to a nicotine patch or placebo for 10 weeks. After
a three-year follow-up, continuous cigarette absti-
nence rates were significantly higher in those individ-
uals treated with the patch (13.8 versus 5.2 percent for
placebo).16 Studies assessing the efficacy of either nasal
spray or inhaler showed one year-quit rates between
26 and 28 % in actively treated patients compared to
10% and 18% with placebo, respectively.17 Additional
success is found in patients who are also given sup-
portive counselling.4
The few side effects, which appear to interfere with
use of the patch, aremild skin sensitivity, leading rarely
towithdrawal of patch use, aswell as sleep disturbance
for some smokers using the 24-hour patch.18 The major
side effects usually reportedwith nicotine gum, includ-
ing hiccoughs, gastrointestinal disturbances, jaw pain,
and orodental problems.4 The major side effects re-
ported with the nicotine inhaler and nasal spray are re-
lated to local irritation at the site of administration
401Smoking Cessation Clinical Practice(mouth and nose respectively).4 Symptoms such as
throat irritation, coughing, and oral burning were re-
ported significantly more frequently with subjects allo-
cated to the nicotine inhaler than to placebo control.19
None of the experiences, however, were reported as se-
vere. With the nasal spray, nasal irritation and runny
nose are the most commonly reported side effects. Nic-
otine sublingual tablets have been reported to cause
hiccoughs, burning and smarting sensation in the
mouth, sore throat, coughing, dry lips and mouth
ulcers.20
There has been concern about the safety of NRT in
smokers with cardiac disease. A review of adverse ef-
fects based on 35 trials with over 9 000 participants
did not find evidence of excess adverse cardiovascu-
lar events assigned to nicotine patch, and the total
number of such events was low.18 A trial of nicotine
patches, which recruited smokers aged over 45 with
at least one diagnosis of cardiovascular disease, found
no evidence that serious adverse events were more
common in smokers in the nicotine patch group.21
Events related to cardiovascular disease such as in-
crease in angina severity occurred in approximately
16% of patients, but did not differ according to
whether or not patients were receiving NRT. There-
fore NRT should not be contraindicated in patients
with cardiovascular or cerebrovascular disease.22
NRT may be prescribing during pregnancy and
breast-feeding when a woman in preparation stage
cannot quit smoking with behavioural approach.2
Ex-smokers using NRT for a long time (e.g., several
months) might become dependent on the product
and therefore have difficulty weaning themselves off
it. To our knowledge, there is no data assessing the in-
cidence of such NRT dependence. However, this situ-
ation seems to be very rare.
Bupropion
The main alternative pharmacological treatment to
nicotine replacement therapy is bupropion, which
has been shown to be effective.23e25 A Cochrane re-
view of the evidence for bupropion in smoking cessa-
tion identified 24 studies giving data on over 6 000
patients. Ten studies had information on abstinence
rates at one year. Meta-analysis of the data from 19 tri-
als showed an odds ratio of around 2 in favour of
smoking cessation, although studies lasted variable
lengths of time.25
Bupropion is an anti-depressant, which inhibits
noradrenaline and dopamine reuptake, thereby in-
creasing levels within the brain. Its mechanism of ac-
tion in smoking cessation is unclear, although it isthought that dopaminergic pathways are involved in
the ‘‘reward’’ circuit of drug dependence. The positive
reinforcing effects of nicotine are due increased dopa-
mine release in the nucleus accumbens. Therefore, in-
creased dopamine release by bupropion will decrease
withdrawal symptoms. It also is hypothesised that
bupropion may act as an antagonist at the nicotinic
acetylcholine receptor. Although it is possible that
the anti-depressant effects of bupropion contribute
to its benefits in depressed smokers, it has been
shown to be efficacious in patients who are not de-
pressed making it unlikely that this is the sole
explanation.
Bupropion should be initially prescribed at 150 mg
once a day, increasing to twice a day after 6 days, if
tolerated. Peak plasma concentrations are reached at
3 hours after dosage. Both bupropion and its three ac-
tive metabolites are conjugated within the liver to in-
active metabolites, which are excreted in the urine.
Elimination half-life is 20 hours.24
Bupropion and its main metabolite inhibit CYP2D6,
leading to possible increases in plasma concentrations
of particular antidepressants (desipramine, imipra-
mine, paroxetine), antipsychotics (thioridazine, risper-
idone), type 1C antiarrhythmics and metoprolol.
Bupropion is metabolised via CYP2B6 and should be
used with care in combination with medication,
which inhibits or induces this enzyme. For example
anticonvulsants such as phenytoin and carbamaze-
pine may induce metabolism, whereas valproate
may inhibit metabolism, as does ritonavir. The possi-
bility of a pharmacokinetic interaction with alcohol
has been raised in case reports describing reduced al-
cohol tolerance and increased psychiatric effects. The
manufacturers advise that alcohol intake is avoided
whilst taking bupropion. Drugs with dopaminergic
effects such as monoamine oxidase inhibitors, levo-
dopa and amantidine may produce increased side ef-
fects when prescribed with bupropion.
In one study bupropion was found to be signifi-
cantly more effective than nicotine patch.26 However,
nicotine patch itself was not efficacious in this partic-
ular study. Additionally bupropion and nicotine patch
were combined and appeared to increase quit rates
more than patch alone (OR 2.65, 95% CI 1.58 to
4.45).26 In a study assessing bupropion for re-treating
smokers who had just failed to quit with NRT, only
one participant, from the bupropion treatment arm,
was abstinent after six months.27
The most frequent side effects are insomnia, occur-
ring in 30% to 40% of patients, dry mouth (10%) and
nausea (5e10%). Typical dropout rates, due to ad-
verse events, range from 7% to 31%. Allergic reactions
reported with bupropion include pruritus, hives,
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3 per thousand.25 Using a slow release (SR) prepara-
tion in doses of 300 mg/day or less, and excluding
those at risk of seizures, no seizures had been re-
ported in any of the smoking cessation trials until
a European enrolling study28 reported two seizures
amongst 502 people randomised to bupropion. A
much larger, open, uncontrolled observational safety
surveillance study conducted by the manufacturers29
examined 3 100 adult patients using slow release bu-
propion for eight weeks for treatment of depression
(not smoking cessation). Treatment was extended if
necessary to a year, at a maximum dose of 150 mg
twice daily. Patients with a history of eating disorder,
or a personal or family history of epilepsy were
excluded. Three participants (0.1%) had a seizure
considered to be related to the therapeutic use of bu-
propion. Post-marketing surveillance, does not report
any higher rates of seizure.24
Although no patient was reported to have died
while taking bupropion in trials for smoking cessation,
some have died while taking bupropion prescribed for
smoking cessation in routine practice. There has been
no formal epidemiological analysis of these deaths,
but no national reporting scheme has concluded that
bupropion caused these deaths. Bupropion may cause
adverse effects in overdose. A review of bupropion
non-therapeutic exposures reported to the US Toxic
Exposure Surveillance System for 1998e1999 identi-
fied 7 348 exposures to bupropion, prescribed either
for depression or smoking cessation, and concluded
that the extent of toxicity for bupropion was compara-
ble to other antidepressants such as selective serotonin
reuptake inhibitors (SSRIs).30
Other drugs and clinical interventions
Varenicline is an alpha4 beta2 nicotinic acetylcoline
receptor partial agonist and was designed for smok-
ing cessation. This drug works by reducing the
strength of the smoker’s urge to smoke and by reliev-
ing withdrawal symptoms.31 It is structurally similar
to cytosine, prescribed as a smoking cessation drug
for many years in Central Europe. The alpha4 beta2
receptors play a role in the rewarding system of nico-
tine by modulating the release of neurotransmitters
such as dopamine in the nucleus accumbens, ‘‘the re-
ward centre’’ of the brain. Varenicline mimics the ef-
fect of nicotine and hence reduces craving when
smokers stop. Furthermore, varenicline blocks nico-
tine receptors and, in this manner, provokes a weaker
response to nicotine if smokers use tobacco products
while taking the drug. Thus, the smoker experiences
Eur J Vasc Endovasc Surg Vol 34, October 2007less satisfaction from smoking. In clinical studies,
the short-term and long-term cessation rate of vareni-
cline exceeded that of placebo or bupropion.32,33 Var-
enicline appears to be safe and well tolerated in
healthy smokers. Nausea, the most frequent side ef-
fects, was reported as being mostly mild to moderate
in severity and rarely resulted in discontinuation of
study medication. Data for cardiovascular disease
patients are lacking.
Several antidepressants, apart from buproprion,
have been assessed for smoking cessation. There
was one trial of the monoamine oxidase inhibitor mo-
clobemide, and one of the atypical antidepressant
venlafaxine. Neither of these detected a significant
long-term benefit. There were five trials of SSRIs;
three of fluoxetine, one of sertraline and one of parox-
etine. There was no evidence of a significant benefit
when results were pooled.25
Other medications, which have been tried, include
mecamylamine (non-competitive nicotinic receptor
antagonist), clonidine (a centrally acting antihyperten-
sive), buspirone (and other anxiolytics), lobeline (a
nicotine like alkaloid) and naloxone.4 Little evidence
is currently available to support the use of any of
these agents.
Patients often express interest in smoking cessa-
tion via hypnosis. Its popularity is understandable,
because it implies smoking cessation can be effected
without effort or distress. However, several reviews
of the literature have found insufficient evidence
that hypnosis offers any additional treatment advan-
tage above and beyond the behavioural and pharma-
cotherapeutic interventions that may be bundled
together with it.4 It is noteworthy that research liter-
ature is lacking in properly controlled studies and
that the smoking cessation interventions offered by
hypnotherapists are quite variable in terms of their
other treatment components. Given the lack of
evidence for their efficacy, hypnosis-based treatments
cannot currently be routinely recommended for
smoking cessation.
The use of acupuncture for smoking cessation also
appears to be growing in popularity. However,
meta-analysis found that ‘‘active’’ acupuncture did
not outperform ‘‘control’’ acupuncture, suggesting
that acupuncture itself is not a potent intervention.4
Selective central cannabinoid receptor antagonists
represent a novel pharmaceutical approach to smoking
cessation.34 One of them, Rimonabant, has been devel-
oped as a treatment for both smoking and obesity, and
results of phase III human trials for smoking are pend-
ing. The use of dextrose has been investigated since the
‘urge’ to smokemay be due to a mislabelling of a phys-
iological need for carbohydrates. Short-term trials have
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ated in long-term studies.
Preliminary data suggest that vaccine-targeting nic-
otine may help smokers quit. Nicotine vaccine is de-
signed to stimulate the production of antibodies. The
basic premise is that such antibodies might block
some of nicotine’s reinforcing effects by sequestering
the chemical in blood and preventing it from reaching
the brain. Results from phase I trials show that such
a vaccine appears to bewell tolerated andpromotes im-
munological responses to the majority of the study
participants.35
Relapse prevention
Even the most effective interventions are plagued by
relapse. Clinicians should tell the patient that the typ-
ical smoker requires several serious quitting attempts
before finally achieving long-term success. Although
the patient must enter each quitting attempt moti-
vated by the expectation of success, setbacks should
be viewed as learning experiences. With each relapse,
the patient learns more about his/her personal
strengths and vulnerabilities, the nature of nicotine
addiction and relapse risk factors for which the pa-
tient needs to prepare better in the future. Indeed, to-
bacco use should be defined as a ‘‘chronic condition
that often requires repeated intervention’’. Patients
should be advised to avoid any tobacco use at all after
cessation and warned that many of those who have
a single post-cessation cigarette eventually return to
daily smoking. Relapse-prevention strategies have
been found to be effective as a treatment component
for tobacco use. Therefore, the clinician should exe-
cute the last of the ‘‘5 A’s’’: Arrange follow-up and re-
lapse prevention. Clinicians should arrange for either
a formal or phone follow-up contact with the patient
shortly after the target quit date. By arranging for
such a contact, the clinician emphasizes the impor-
tance of quitting smoking and communicates personal
support for the patient’s effort. The contact itself pro-
vides an opportunity to offer additional encourage-
ment and support, to monitor the patient’s progress,
and to provide further assistance (e.g., adjustment of
pharmacotherapy instructions, referral to an intensive
program, advice about weight gain). Patients can
benefit from extended contact by receiving a series
of printed relapse-prevention materials through the
mail over an extended period of time.36
In case of relapse, clinicians should tell the patient
that the most smokers require several serious quitting
attempts before finally achieving long-term success.
Although the patient must enter each attempt moti-
vated by the expectation of success, setbacks shouldbe viewed as learning experiences. With each relapse,
the patient learns more about personal strengths and
vulnerabilities, the nature of nicotine addiction, and
relapse risk factors.
Conclusion
The ‘‘5 A’s’’ recommended by the clinical practice
guidelines typically require only a few minutes of di-
rect clinician time. Counselling and pharmacothera-
peutic interventions for smoking cessation are
among the most cost-effective clinical interven-
tions.37,38 Smoking cessation interventions systemati-
cally provided to smokers during physician-patient
contacts have the aggregate potential to produce a dra-
matic enhancement of public health. Doctors and
other medical personnel should assess, advise, and as-
sist smokers at every opportunity. For smokers ready
to quit, the physician should show strong support,
help set a quit date, prescribe pharmaceutical thera-
pies for nicotine dependence, such as nicotine replace-
ment therapy and/or an effective drug such as
bupropion or varenicline, with instructions for use,
and suggest behavioural strategies to prevent relapse.
Box
Nicotine replacement therapies and bupropion
are effective to help smokers quit and should be
considered as the two first line therapies. Vareni-
cline (now licensed in the UK) has the potential to
be considered as a first-line therapy. Combining
behavioural support and nicotine replacement
therapy will increase success rates over either
treatment alone. Using two different forms of
NRT could have an effect by producing higher
blood nicotine levels, however the incremental
success produced by combination NRTs may de-
pend on the use of two distinct delivery systems:
one passive and one ad libitum. Use of the patch
to establish a background level of nicotine, com-
bined with using gum, inhaler/inhalator or nasal
spray when cravings occur, may provide better
control of withdrawal. There is no evidence that
using more than one form is likely to lead to nic-
otine overdose. Clinicians should not forget that
smoking is not only individual behaviour due
to nicotine dependence, but also the consequence
of several economic and social factors, such as
cigarettes price, marketing and social norms,
which require integrating into the assessment
and advice of a smoker.
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